Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | LDHB | P07195 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23201986 | 1.00 | HDAC6 (0.66) | HDAC6HDAC1HDAC3HDAC2IDH1 | |
| SCHEMBL23202628 | 1.00 | HDAC6 (0.66) | HDAC6HDAC1HDAC3HDAC2IDH1 | |
| SCHEMBL23202410 | 0.94 | HDAC6 (0.59) | HDAC6HDAC1HDAC3HDAC2LDHA | |
| SCHEMBL23202581 | 0.94 | HDAC6 (0.59) | HDAC6HDAC1HDAC3HDAC2LDHA | |
| SCHEMBL23202562 | 0.87 | HDAC6 (0.69) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL23203640 | 0.80 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL23202419 | 0.80 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL23202461 | 0.80 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL23167347 | 0.79 | HDAC6 (0.56) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL25138242 | 0.79 | HDAC6 (0.54) | HDAC6HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2021067859-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | HDAC6, HDAC1, HDAC2 | HDAC6 1/4885HDAC1 2/4885HDAC3 4/4885 |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | SLC28A1, SLC5A1, SLC9A5 | HDAC6 40/4885HDAC1 60/4885HDAC3 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.